期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 24, 期 3, 页码 199-208出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/09546634.2012.713462
关键词
efficacy; etanercept; long-term treatment; psoriasis; TNF
类别
资金
- Pfizer, Italy
- Meda
- Lohmann Rauscher
- ConvaTec
- Pfizer
- 3M
- Astellas
- Almirall
- Novartis
- Abbott
- Janssen
- GSK
- Schering-Plough
- Wyeth
- Leo Pharma
- Merck-Serono
- MSD
- UCB
- Celgene
The treatment of psoriasis requires long-lasting intervention. Conventional treatments for psoriasis comprise topical, phototherapeutic and systemic modalities, such as methotrexate or cyclosporine. Biological therapies are advocated by treatment guidelines for the use in moderate-to-severe psoriasis, when conventional treatments have failed, are contraindicated or are associated with severe adverse events. Etanercept is an anti-TNF recombinant fusion protein that has emerged as a standard biologic treatment option for moderate-to-severe psoriasis. The present review summarizes data from pivotal and post-marketing randomized controlled etanercept trials to treat moderate-to-severe psoriasis for 24 weeks and longer. During the first 12 weeks, etanercept can be administered in different dosing regimens: 50 mg twice weekly (BIW) and 50 mg once weekly. Although both regimens are effective, it has been shown that the 50 mg BIW dosage leads to higher response rates at week 24. In addition, after 24 weeks' treatment etanercept provides the unique possibility of continuous or intermittent long-term treatment programmes. The medium-to long-term efficacy of etanercept was consistent, regardless of whether etanercept therapy was interrupted or continuous. Taking the chronic nature of psoriasis into account, this flexibility in dosing regimen bestows a key advantage in facilitating individualisation of long-term treatment according to patient needs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据